CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

VectivBio Holding AG

VECT
N/A

Next catalyst

Phase 3Q4 2027

Apraglutide

Short Bowel Syndrome

Get an email about VECT's next catalysts

Track VectivBio Holding (VECT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 0 past

Phase 3Next

Apraglutide Phase 3 Est. Readout (STARS extend)

Q4 2027~QApraglutide158

Primary completion for Apraglutide trial (NCT05018286) in Short Bowel Syndrome

Source

Market Overview

Stock performance and key metrics

NASDAQBiotechnologyπŸ‡ΊπŸ‡ΈNorth America
Drug Pipeline

Frequently asked questions

What is in VectivBio Holding AG's drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in VectivBio Holding AG's (VECT) pipeline across Phase 3, Phase 2. Its lead program is Apraglutide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is VectivBio Holding AG's next FDA catalyst?β†’

VectivBio Holding AG's (VECT) next tracked catalyst is a Phase 3 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track VECT biotech catalysts?β†’

Add VECT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VectivBio Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply